Table 1 Demographic and clinical characteristics of cohorts 1 and 2
Subtype | Cohort 1 | Cohort 2 | |||||
|---|---|---|---|---|---|---|---|
HCÂ (%) | Luminal (%) | TN (%) | HER2-enriched (%) | Luminal (%) | TN (%) | HER2-enriched (%) | |
Total | 98 | 138 | 143 | 127 | 10 | 10 | 10 |
Age | |||||||
 Mean | 44.99 | 61.3 | 57.3 | 59.6 | 66 | 64.1 | 62.1 |
 < 40 | 33 (33.6) | 5 (3.6) | 17 (11.9) | 6 (4.7) | 1 (10) | 0 | 0 |
 40–49 | 26 (26.5) | 18 (13.0) | 24 (16.8) | 25 (19.6) | 0 | 1 (10) | 2 (20) |
 50–59 | 24 (24.5) | 43 (31.2) | 37 (25.9) | 34 (26.8) | 3 (30) | 2 (20) | 3 (30) |
 60–69 | 14 (14.3) | 37 (26.8) | 31 (21.7) | 31 (24.4) | 1 (10) | 3 (30) | 3 (30) |
 > 70 | 1 (1.0) | 35 (25.3) | 34 (23.7) | 31(24.4) | 5 (50) | 4 (40) | 2 (20) |
Histological grade | |||||||
 1 |  | 34 (24.6) | 0 | 0 | 0 | 0 | 0 |
 2 |  | 62 (44.9) | 52 (36.4) | 34 (26.8) | 0 | 0 | 0 |
 3 |  | 42 (30.4) | 91 (63.6) | 93 (73.2) | 10 (100) | 10 (100) | 10 (100) |
Tumor size | |||||||
 < 2 cm |  | 58 (42.0) | 68 (47.6) | 43 (33.8) | 2 (20) | 2 (20) | 1 (10) |
 2.0–5.0 cm |  | 57 (41.3) | 72 (50.3) | 65 (51.2) | 5 (50) | 8 (80) | 8 (80) |
 > 5 cm |  | 23 (16.7) | 3 (2.1) | 18 (14.2) | 3 (30) | 0 | 1 (10) |
 Not available |  | 0 | 0 | 1 (0.8) | 0 | 0 | 0 |
PR status | |||||||
 Positive |  | 138 (100) | 0 (0) | 0 (0) | 8 (80) | 0 (0) | 12 (9.4) |
 Negative |  | 0 (0) | 143 (100) | 127 (100) | 2 (20) | 10 (100) | 115 (90.6) |
HER2 IHC | |||||||
 Positive |  | 119 (86.2) | 0 (0) | 12 (9.4) | 0 (0) | 0 (0) | 10 (100) |
 Negative |  | 19 (13.8) | 143 (100) | 115 (90.6) | 10 (100) | 10 (100) | 0 (0) |